Prurigo

A new study found that the Worst Itch Numeric Rating Scale is a valid and reliable instrument to capture itch data of patients with prurigo nodularis.

Abrocitinib may be an effective and well-tolerated treatment for adults with prurigo nodularis and chronic pruritus of unknown origins, according to a study.

Galderma has received filing acceptances for nemolizumab for the treatment of prurigo nodularis and atopic dermatitis in Australia, Singapore, Switzerland and the United Kingdom, the company announced in a press release.

Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.

SAN DIEGO — At the American Academy of Dermatology Annual Meeting, Galderma announced new data demonstrating nemolizumab’s long-term efficacy in treating prurigo nodularis and atopic dermatitis, according to a press release.

The FDA and the European Medicines Agency have accepted applications for nemolizumab for the treatment of prurigo nodularis and severe atopic dermatitis in adolescents and adults, Galderma announced in a press release.

Researchers have developed and validated a new tool for evaluating disease control among patients with chronic prurigo, according to a study.

Nemolizumab monotherapy significantly reduced the signs and symptoms of prurigo nodularis, including sleep disturbance, according to results from a phase 3 study.

Galderma has announced positive data from three phase 3 studies that evaluated nemolizumab for the treatment of atopic dermatitis and prurigo nodularis, according to a company press release.